National Asthma Education and Prevention Program: Expert Panel Report 2. Guidelines for the diagnosis and management of asthma: Translating research for clinicians and patients

ABSTRACTAsthma is a chronic, inflammatory disease of the airways that exacts a large burden of illness among patients, their families, and the health-care system. Yet advances in research have generated the means for addressing this public health problem. The challenge is to bridge the gap between excessive asthma morbidity and the science that holds the promise of reducing it; that is, to translate the scientific advances into meaningful recommendations for clinical care and to promote adoption of the recommendations. This paper will demonstrate how national asthma education programs, founded on science-based clinical practice guidelines, meet this challenge and help reduce illness and improve the quality of life for people with asthma

Definition of Metabolic Syndrome: Report of the National Heart, Lunch, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition

https://www.ahajournals.org/doi/pdf/10.1161/01.atv.0000111245.75752.c

Respiratory Control in the Lungfish, Neoceratodus Forsteri (Krefft)

1. Respiratory control has been studied in the lungfish, Neoceratodus forsteri by measuring ventilation (Ve), oxygen uptake (VO2), per cent O2 extraction from water, breathing rates of branchial and aerial respiration and changes in blood gas and pulmonary gas composition during exposure to hypoxia and hypercarbia. 2. Hypoxic water represents a strong stimulus for compensatory increase in both branchial and aerial respiration. Water ventilation increases by a factor of 3 or 4 primarily as a result of increased depth of breathing. 3. The ventilation perfusion ratio decreased during hypoxia because of a marked increase in cardiac output. Hypoxia also increased the fraction of total blood flow perfusing the lung. Injection of nitrogen into the lung evoked no compensatory changes. 4. It is concluded that the chemoreceptors eliciting the compensatory changes are located on the external side facing the ambient water or in the efferent branchial blood vessels. 5. Elevated pCO2 in the ambient water depressed the branchial respiration but stimulated aerial respiration. 6. It is suggested that the primary regulatory effect of the response to increased ambient pCO2 is to prevent CO2 from entering the animal, while the secondary stimulation of air breathing is caused by hypoxic stimulation of chemoreceptors located in the efferent branchial vessels

Brain metabolic abnormalities during gait with freezing in Parkinson’s disease

International audienc

Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

The National Cholesterol Education Program’s Adult Treatment Panel III report (ATP III)1 identified the metabolic syndrome as a multiplex risk factor for cardiovascular disease (CVD) that is deserving of more clinical attention. The cardiovascular community has responded with heightened awareness and interest. ATP III criteria for metabolic syndrome differ somewhat from those of other organizations. Consequently, the National Heart, Lung, and Blood Institute, in collaboration with the American Heart Association, convened a conference to examine scientific issues related to definition of the metabolic syndrome. The scientific evidence related to definition was reviewed and considered from several perspectives: (1) major clinical outcomes, (2) metabolic components, (3) pathogenesis, (4) clinical criteria for diagnosis, (5) risk for clinical outcomes, and (6) therapeutic interventions

Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition

The National Cholesterol Education Program’s Adult Treatment Panel III report (ATP III)1 identified the metabolic syndrome as a multiplex risk factor for cardiovascular disease (CVD) that is deserving of more clinical attention. The cardiovascular community has responded with heightened awareness and interest. ATP III criteria for metabolic syndrome differ somewhat from those of other organizations. Consequently, the National Heart, Lung, and Blood Institute, in collaboration with the American Heart Association, convened a conference to examine scientific issues related to definition of the metabolic syndrome. The scientific evidence related to definition was reviewed and considered from several perspectives: (1) major clinical outcomes, (2) metabolic components, (3) pathogenesis, (4) clinical criteria for diagnosis, (5) risk for clinical outcomes, and (6) therapeutic interventions

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

The voluntary withdrawal of cerivastatin (Baycol) from the U.S. market on August 8, 2001, by the manufacturer, in agreement with the Food and Drug Administration (FDA), has prompted concern on the part of physicians and patients regarding the safety of the cholesterol-lowering class of drugs called HMG CoA reductase inhibitors, more commonly known as “statins.” This American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute (ACC/AHA/NHLBI) Clinical Advisory is intended to summarize for professionals the current understanding of statin use, focused on myopathy, and to provide updated recommendations for the appropriate use of statins, including cautions, contraindications, and safety monitoring for statin therapy. Its purpose is not to discourage the appropriate use of statins, which have life-saving potential in properly selected patients, particularly those with established coronary heart disease (CHD) and others at high risk for developing CHD. Included are recent myopathy information compiled by the FDA, information from clinical trials, and summaries from the recently released report of the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP)

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

The voluntary withdrawal of cerivastatin (Baycol) from the U.S. market on August 8, 2001, by the manufacturer, in agreement with the Food and Drug Administration (FDA), has prompted concern on the part of physicians and patients regarding the safety of the cholesterol-lowering class of drugs called HMG CoA reductase inhibitors, more commonly known as “statins.” This American College of Cardiology/American Heart Association/National Heart, Lung and Blood Institute (ACC/AHA/NHLBI) Clinical Advisory is intended to summarize for professionals the current understanding of statin use, focused on myopathy, and to provide updated recommendations for the appropriate use of statins, including cautions, contraindications, and safety monitoring for statin therapy. Its purpose is not to discourage the appropriate use of statins, which have life-saving potential in properly selected patients, particularly those with established coronary heart disease (CHD) and others at high risk for developing CHD. Included are recent myopathy information compiled by the FDA, information from clinical trials, and summaries from the recently released report of the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program (NCEP)

Country activities of Global Alliance against Chronic Respiratory Diseases (GARD): focus presentations at the 11th GARD General Meeting, Brussels

© Journal of Thoracic Disease. All rights reserved.The Global Alliance against Chronic Respiratory Diseases (GARD) is a voluntary network of national and international organizations, institutions and agencies led by the World Health Organization (WHO), working towards the vision of a world where all people breathe freely (1). GARD is supporting WHO in successfully implementing the WHO’s Global Action Plan for the Prevention and Control of Noncommunicable Diseases (NCDs) 2013–2020. The GARD report on GARD activities is published on a regular basis. Collaboration among GARD countries is critical for sharing experiences and providing technical assistance to developing countries based on each country’s needs (2). The annual GARD meeting is a unique opportunity for assembling all of the GARD participants from developed and developing countries: European countries, North and South American Countries, China, Vietnam as well as Eastern Mediterranean, and African countries. Coordinator for Management of NCDs in the WHO Department for Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention (Cherian Varghese) is present at this meeting. The annual meeting of GARD is a forum for exchanging opinions in order to improve care for chronic respiratory diseases (CRDs) and to achieve the GARD goal—a world where all people breathe freely. Experts—in collaboration with WHO—are helping developing countries to achieve their projects regarding teaching, research and programming for CRD. Each year, there is a poster presentation session on country activities. Each participant is able to present his/her country activities that have been achieved since the last meeting. This is followed by discussion. In this paper, we summarize the posters presented during the 11th GARD general meeting. We hope that this will give readers of the GARD section an opportunity to learn for their countries. We can find all posters on the link: https://gard-breathefreely.org/resources-poster/.info:eu-repo/semantics/publishedVersio